Regorafenib potently blocks several protein kinases that are involved in tumor angiogenesis (VEGFRs 1–3), oncogenesis (BRAF, RAF, RET, KIT), metastasis (FGFR, PDGFR, VEGFR3) and tumor microenvironment (TME) signaling (Tie2, CSF1R). Here, PDGFRB is linked to neoplasm.